Evidence map›Paper›PMID 26310546›Full record

ArticleInternational urogynecology journal2016

Urinary nerve growth factor and a variable solifenacin dosage in patients with an overactive bladder.

Seyfettin Ciftci, Cuneyd Ozkurkcugil, Hasan Yilmaz, Murat Ustuner, Ufuk Yavuz, Mustafa Yuksekkaya, Mustafa Baki Cekmen

Registry-linked trialAbstract read
PubMed Publisher
In one paragraph

Article in International urogynecology journal, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04693897 (To Explore the Effect of beta3-adrenoceptor Agonist on Patients With Overactive Bladder and Develop Its Urinary Biomarker), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04693897 unknown statusnot on this mapstarted 2021, after this paper: background citation

To Explore the Effect of beta3-adrenoceptor Agonist on Patients With Overactive Bladder and Develop Its Urinary Biomarker

Typeobservational_patient_registrySponsorChang Gung Memorial HospitalRan2021 to 2022Enrolled400ConditionsOveractive Bladder Syndrome, Detrusor OveractivityArmsMirabegron 50 MG, Solifenacin Succinate 5 MG
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Combination of Luteolin and Solifenacin Improves Urinary Dysfunction Induced by Diabetic Cystopathy in Rats.Medical science monitor : international medical journal of experimental and clinical research · 2018
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Seyfettin CiftciDepartment of Urology, Sivas Numune Hospital, Sivas, Turkey. seyfettinciftci@yahoo.com.
Cuneyd OzkurkcugilDepartment of Urology, School Medicine, University of Kocaeli, Kocaeli, Turkey.
Hasan YilmazDepartment of Urology, School Medicine, University of Kocaeli, Kocaeli, Turkey.
Murat UstunerDepartment of Urology, School Medicine, University of Kocaeli, Kocaeli, Turkey.
Ufuk YavuzDepartment of Urology, School Medicine, University of Kocaeli, Kocaeli, Turkey.
Mustafa YuksekkayaDepartment of Urology, School Medicine, University of Kocaeli, Kocaeli, Turkey.
Mustafa Baki CekmenDepartment of Biochemistry, School of Medicine, University of Kocaeli, Kocaeli, Turkey.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introduction and hypothesisWe evaluated changes in urinary nerve growth factor (NGF) and NGF/creatinine (NGF/Cr) levels after increasing the dosage of solifenacin in overactive bladder patients.

methodsThe study groups included 59 overactive bladder (OAB) patients and 20 healthy subjects as controls. We measured NGF at baseline for the patients and controls, and used the Overactive Bladder Awareness Tool (OAB-V8) to evaluate urinary symptoms. All patients received a treatment of solifenacin 5 mg for 6 weeks. The responders to treatment served as group 1 and nonresponders received solifenacin 10 mg for an additional 6 weeks. Responders and nonresponders to the 10-mg treatment were defined as groups 2 and 3 respectively. NGF was measured after each treatment using the ELISA method and normalized by the urinary creatinine levels (NGF/Cr).

resultsThere were 21, 22 and 16 patients in groups 1, 2, and 3 respectively. At baseline, the NGF and NGF/Cr levels were higher in groups 1, 2, and 3 compared with the controls. After the solifenacin 5 mg treatment, the NGF and NGF/Cr levels of group 1 individuals decreased to those of the control level. After increasing the dosage of solifenacin to 10 mg in group 2, the NGF and NGF/Cr levels decreased to normal levels. In group 3 (patients who did not responded to any treatment), these levels remained unchanged.

conclusionsOur results suggest that urinary NGF could be a potential biomarker for monitoring the treatment of symptoms in OAB patients who are treated with solifenacin.

Indexed as

AdultBiomarkersCase-Control StudiesCreatinineHumansMiddle AgedMuscarinic AntagonistsNerve Growth FactorProspective StudiesSolifenacin SuccinateSymptom AssessmentUrinary Bladder, OveractiveBiomarkersCreatinineMuscarinic AntagonistsNerve Growth FactorSolifenacin SuccinateNerve growth factorOveractive bladderSolifenacinTreatment refractory

Identifiers

PMID26310546

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.